Cabotegravir+rilpivirine long-acting every 2 months in a real-world setting: 24-month outcomes in people with HIV-1

AIDS 2026 Open access

Read full text
Authors: Christoph Wyen, Celia Jonsson‐Oldenbüttel, Sebastian Noé, Jan Borch, Kevin Ummard-Berger, Heribert Hillenbrand, Anja Verena Potthoff, Christiane Cordes, Elena Rodriguez, Niels Schübel, Stefan Scholten, Kathrin M. Dymek
+4 more Lori A. Gordon, Patricia de los Rios, Bernd Westermayer, Jenny Scherzer
DOI: 10.1097/qad.0000000000004448
Cited by: 0

Abstract

OBJECTIVE: To describe Month (M) 24 outcomes following switch to cabotegravir plus rilpivirine long-acting (CAB+RPV LA) in the CARLOS study. DESIGN: A noninterventional, 3-year, multicenter study. METHODS: M24 effectiveness outcomes included virologic suppression (HIV-1 RNA

Fields of Study & Subjects

HIV/AIDS drug development and treatment HIV/AIDS Research and Interventions HIV Research and Treatment

Publication details

Journal / source
AIDS
Volume
40
Issue
6
Pages
733–743
Publication date
20 January 2026
Language
EN